S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis (2013)
- Authors:
- USP affiliated authors: COGLIATI, BRUNO - FMVZ ; LIMA, FABIANA ROBERTO - HU ; ALVES, VENANCIO AVANCINI FERREIRA - FM ; CARRILHO, FLAIR JOSÉ - FM ; OLIVEIRA, CLAUDIA PINTO MARQUES SOUZA DE - FM
- Unidades: FMVZ; HU; FM
- DOI: 10.2147/DDDT.S43930
- Subjects: CIRROSE HEPÁTICA (ETIOLOGIA); MODELOS ANIMAIS; HEPATOPATIAS; REAÇÃO EM CADEIA POR POLIMERASE; SEQUENCIAMENTO GENÉTICO; BIOQUÍMICA CELULAR
- Language: Inglês
- Imprenta:
- Source:
- Título: Drug Design, Development and Therapy
- ISSN: 1177-8881
- Volume/Número/Paginação/Ano: v. 7, p. 553-563, 2013
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
MAZO, Daniel Ferraz de Campos et al. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Design, Development and Therapy, v. 7, p. 553-563, 2013Tradução . . Disponível em: https://doi.org/10.2147/DDDT.S43930. Acesso em: 01 abr. 2026. -
APA
Mazo, D. F. de C., Oliveira, M. G. de, Pereira, I. V. A., Cogliati, B., Stefano, J. T., Souza, G. F. P. de, et al. (2013). S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Design, Development and Therapy, 7, 553-563. doi:10.2147/DDDT.S43930 -
NLM
Mazo DF de C, Oliveira MG de, Pereira IVA, Cogliati B, Stefano JT, Souza GFP de, Rabelo F, Lima FR, Alves VAF, Carrilho FJ, Oliveira CPMS de. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Internet]. Drug Design, Development and Therapy. 2013 ; 7 553-563.[citado 2026 abr. 01 ] Available from: https://doi.org/10.2147/DDDT.S43930 -
Vancouver
Mazo DF de C, Oliveira MG de, Pereira IVA, Cogliati B, Stefano JT, Souza GFP de, Rabelo F, Lima FR, Alves VAF, Carrilho FJ, Oliveira CPMS de. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Internet]. Drug Design, Development and Therapy. 2013 ; 7 553-563.[citado 2026 abr. 01 ] Available from: https://doi.org/10.2147/DDDT.S43930 - Experimental models of liver fibrosis
- Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
- The combination of probiotics and prebiotics supplementation improves lipid metabolism, NAFLD and obesity in ob/ob mice
- Survivin expression patterns could reflect different roles in hepatocarcinogenesis, especially in non-alcoholic fatty liver disease-related hepatocellular carcinoma [Carta]
- Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C
- Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis
- P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC
- Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial
- Quantification of experimental liver fibrosis with a novel algorithm method based on statistical analysis of signals
- Ultrasonographic elastography improves early detection of hepatocellular carcinoma in an experimental model of non-alcoholic steatohepatitis
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
